

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Small cell carcinoma | D018288 | — | — | 1 | 1 | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Drug common name | Talabostat |
| INN | talabostat |
| Description | Talabostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target dipeptidyl peptidase 8, dipeptidyl peptidase 4, and dipeptidyl peptidase 9. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O |
| PDB | — |
| CAS-ID | 149682-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL67279 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | KZ1O2SH88Z (ChemIDplus, GSRS) |
